AdC68 Expressing PSA/PSMA/PSCA Vaccine PF-06755992

A prime cancer vaccine comprised of a genetically engineered, replication-deficient chimpanzee adenovirus serotype-68 (AdC68) encoding the tumor-associated antigens (TAAs) human prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA), with potential immunostimulating and antineoplastic activities. Upon administration of AdC68 expressing PSA/PSMA/PSCA priming vaccine PF-06755992, the adenovirus infects and expresses PSA, PSMA and PSCA. The expressed proteins may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing PSA, PSMA and PSCA, thereby inducing tumor cell lysis. PSA, PSMA and PSCA are overexpressed on a variety of cancer cell types.